Ex-No­var­tis busi­ness head hops over to a gene ther­a­py start­up — and she's reeled in $80M for a dash to the clin­ic

Neu­rol­o­gist and King’s Col­lege Lon­don pro­fes­sor Christo­pher Shaw has been re­search­ing neu­rode­gen­er­a­tive dis­eases like ALS and col­lab­o­rat­ing with drug­mak­ers for the last 25 years in the hopes of push­ing new ther­a­pies for­ward. But un­for­tu­nate­ly, none of those ef­forts have come any­where close to fruition.

“So, you know, af­ter 20 years in the game, I said, ‘Let’s try and do it our­selves,’” he told End­points News. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER